Millennium Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Millennium Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$214K	Buy	3,712 +2	+0.1%	+$115	0.12%	131
2026 Q1	$225K	Buy	+3,710	New	+$216K	0.14%	116
2025 Q3	–	Sell	-5,316	Closed	-$246K	–	133
2025 Q2	$246K	Sell	5,316 -47	-0.9%	-$2.31K	0.16%	105
2025 Q1	$327K	Buy	5,363 +17	+0.3%	+$991	0.24%	80
2024 Q4	$302K	Sell	5,346 -198	-4%	-$11.1K	0.21%	84
2024 Q3	$287K	Sell	5,544 -98	-2%	-$4.6K	0.19%	91
2024 Q2	$234K	Sell	5,642 -747	-12%	-$33.4K	0.16%	105
2024 Q1	$346K	Sell	6,389 -560	-8%	-$28.5K	0.24%	75
2023 Q4	$357K	Sell	6,949 -1,018	-13%	-$53.4K	0.27%	63
2023 Q3	$462K	Sell	7,967 -1,099	-12%	-$67.3K	0.39%	53
2023 Q2	$580K	Sell	9,066 -97	-1%	-$6.5K	0.48%	46
2023 Q1	$635K	Buy	9,163 +52	+0.6%	+$3.67K	0.57%	46
2022 Q4	$656K	Sell	9,111 -755	-8%	-$56.9K	0.66%	44
2022 Q3	$701K	Buy	9,866 +13	+0.1%	+$943	0.74%	37
2022 Q2	$759K	Sell	9,853 -49	-0.5%	-$3.73K	0.74%	38
2022 Q1	$723K	Sell	9,902 -525	-5%	-$35.3K	0.58%	40
2021 Q4	$650K	Buy	+10,427	New	+$612K	0.51%	44

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Millennium Capital Advisors's BMY Position: Q2 2026 in Review

Millennium Capital Advisors increased its Bristol-Myers Squibb (BMY) stake by 0.05% in Q2 2026, buying an estimated $115 and bringing the position to 3,712 shares worth $214K. The position accounts for 0.12% of the portfolio, ranked #131.

Millennium Capital Advisors first reported a position in BMY in Q4 2021 and has held it in 17 quarters since. The position peaked at $759K in Q2 2022. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Millennium Capital Advisors held 3,712 shares of Bristol-Myers Squibb worth $214K as of Q2 2026.
Millennium Capital Advisors bought 2 Bristol-Myers Squibb shares in Q2 2026, an estimated $115.
Bristol-Myers Squibb made up 0.12% of Millennium Capital Advisors's portfolio in Q2 2026, its #131 holding.
Millennium Capital Advisors first reported a position in Bristol-Myers Squibb in Q4 2021 and has held it in 17 quarters since.
Millennium Capital Advisors's Bristol-Myers Squibb position peaked at $759K in Q2 2022.
2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Millennium Capital Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.